Expression of Leukaemia Inhibitory Factor in Epithelial Ovarian Carcinoma: Correlation with Clinical Characteristics

F Ye,Y Hu,W Lu,C Zhou,X Xie
DOI: https://doi.org/10.1111/j.1365-2559.2008.03068.x
2008-01-01
Histopathology
Abstract:Sir: Leukaemia inhibitory factor (LIF) is a polyfunctional glycoprotein of the interleukin-6 family of cytokines, which has been shown to induce macrophage maturation and terminate self-renewal of the undifferentiated and highly clonogenic murine myeloid leukaemia M1, resulting in suppression of the leukaemia population. Subsequent studies have revealed that LIF is essential for maintenance of the totipotentiality of normal embryonic stem (ES) cells via inhibition of differentiation and maintenance of proliferation. Abnormal expression of key molecules has the potential to alter the balance between cell proliferation and differentiation, resulting in tumorigenesis. Hence, the ability of LIF to regulate both cell proliferation and differentiation suggests that it might be involved in the carcinogenesis of some tumours, though contradictory results have been reported. Previous studies have detected stem cells in tumour tissues, including ovarian cancer. Since LIF sustains the totipotentiality of ES cells, it is possible that LIF could be involved in the transformation of ovarian epithelial cells and the occurrence and development of epithelial ovarian carcinoma. LIF expression was examined by immunohistochemistry in 401 cases of ovarian epithelial lesions, including 49 normal ovarian epithelia, 91 serous cystadenomas,
What problem does this paper attempt to address?